15-hydroxyprostaglandin dehydrogenase in colorectal mucosa as a potential biomarker for predicting colorectal neoplasms

Journal of Korean Medical Science

Volumn 28, Issue 8, 2013, Pages 1154-1160

  Lee, Neoplasms Hyo Jeong ^a   Yang, Dong Hoon ^a   Ryu, Yeon Mi ^a   Song, Miyeoun ^a   Song, Ho June ^a   Jung, Kee Wook ^a   Kim, Kyung Jo ^a   Ye, Byong Duk ^a   Byeon, Jeong Sik ^a   Choi, Eun Kyung ^a   Yang, Suk Kyun ^a   Kim, Jin Ho ^a   Myung, Seung Jae ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

15 hydroxyprostaglandin dehydrogenase; Biological markers; Colorectal

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; BIOLOGICAL MARKER; MESSENGER RNA; TUMOR MARKER;

AGED; ARTICLE; CANCER STAGING; COLORECTAL TUMOR; DOWN REGULATION; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; INTESTINE MUCOSA; MALE; METABOLISM; MIDDLE AGED; MULTIPLE CANCER; PATHOLOGY; PREDICTIVE VALUE; REAL TIME POLYMERASE CHAIN REACTION; RISK; RISK FACTOR; SECOND CANCER;

15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS;

AGED; COLORECTAL NEOPLASMS; DOWN-REGULATION; FEMALE; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; INTESTINAL MUCOSA; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; ODDS RATIO; PREDICTIVE VALUE OF TESTS; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84884369718     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2013.28.8.1154     Document Type: Article

References (24)

1. Markowitz SD. Aspirin and colon cancer: targeting prevention? N Engl J Med 2007; 356: 2195-8.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
3. Jung KW, Won YJ, Park S, Kong HJ, Sung J, Shin HR, Park EC, Lee JS. Cancer statistics in Korea: incidence, mortality and survival in 2005. J Korean Med Sci 2009; 24: 995-1003.
4. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-60.
5. Srivastava S, Verma M, Henson DE. Biomarkers for early detection of colon cancer. Clin Cancer Res 2001; 7: 1118-26.
6. Cha YI, DuBois RN. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 2007; 58: 239-52.
7. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1: 11-21.
8. Tai HH, Ensor CM, Tong M, Zhou H, Yan F. Prostaglandin catabolizing enzymes. Prostaglandins Other Lipid Mediat 2002; 68-69: 483-93.
9. Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, et al. 15-hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A 2006; 103: 12098-102.
10. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JK, et al. 15-hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A 2004; 101: 17468-73.
11. Smartt HJ, Greenhough A, Ordóñez-Morán P, Talero E, Cherry CA, Wallam CA, Parry L, Al Kharusi M, Roberts HR, Mariadason JM, et al. β-catenin represses expression of the tumour suppressor 15-prostaglandin dehydrogenase in the normal intestinal epithelium and colorectal tumour cells. Gut 2012; 61: 1306-14.
12. Jothy S, Slesak B, Harłozinska A, Lapinska J, Adamiak J, Rabczynski J. Field effect of human colon carcinoma on normal mucosa: relevance of carcinoembryonic antigen expression. Tumour Biol 1996; 17: 58-64.
13. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology 2010; 138: 2029-43.e10.
14. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993; 260: 816-9.
15. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003; 63: 1727-30.
16. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6: 963-8.
17. Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005; 97: 1330-8.
18. Belshaw NJ, Pal N, Tapp HS, Dainty JR, Lewis MP, Williams MR, Lund EK, Johnson IT. Patterns of DNA methylation in individual colonic crypts reveal aging and cancer-related field defects in the morphologically normal mucosa. Carcinogenesis 2010; 31: 1158-63.
19. Worthley DL, Whitehall VL, Buttenshaw RL, Irahara N, Greco SA, Ramsnes I, Mallitt KA, Le Leu RK, Winter J, Hu Y, et al. DNA methylation within the normal colorectal mucosa is associated with pathwayspecific predisposition to cancer. Oncogene 2010; 29: 1653-62.
20. Keku TO, Amin A, Galanko J, Martin C, Schliebe B, Sandler RS. Apoptosis in normal rectal mucosa, baseline adenoma characteristics, and risk of future adenomas. Cancer Epidemiol Biomarkers Prev 2008; 17: 306-10.
21. Martin C, Connelly A, Keku TO, Mountcastle SB, Galanko J, Woosley JT, Schliebe B, Lund PK, Sandler RS. Nonsteroidal anti-inflammatory drugs, apoptosis, and colorectal adenomas. Gastroenterology 2002; 123: 1770-7.
22. Baytner S, Mitmaker B, Gordon PH, Wang E. Immunohistochemical expression of mutant p53 oncogene in transitional mucosa adjacent to human colon cancer. Clin Invest Med 1993; 16: 379-85.
23. Chung SJ, Kim YS, Yang SY, Song JH, Kim D, Park MJ, Kim SG, Song IS, Kim JS. Five-year risk for advanced colorectal neoplasia after initial colonoscopy according to the baseline risk stratification: a prospective study in 2452 asymptomatic Koreans. Gut 2011; 60: 1537-43.
24. Martínez ME, Sampliner R, Marshall JR, Bhattacharyya AK, Reid ME, Alberts DS. Adenoma characteristics as risk factors for recurrence of advanced adenomas. Gastroenterology 2001; 120: 1077-83.